scholarly journals Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Yu-xia Ma ◽  
Xiao Liu ◽  
Cun-zhi Liu ◽  
Lin-peng Wang ◽  
Gang Guo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Adverse Events ◽  
Abdominal Distension ◽  
Clinical Effects ◽  
End Of Treatment ◽  
Significant Difference ◽  
Irritable Bowel

Objective. To explore the efficacy of Herb-partitioned moxibustion in treating IBS-D patients.Method. 210 IBS-D patients were randomly assigned on a3:3:2basis to group HM, group FM, or group PB for 4-week treatment. The change of GSRS total score at weeks 4 and 8, the changes of GSRS specific scores, and adverse events were evaluated.Results. Patients in group HM and group FM had lower GSRS total score at week 4 (1.98±0.303,2.93±0.302versus3.73±0.449) and at week 8 (2.75±0.306,3.56±0.329versus4.39±2.48) as compared with patients’ score in group PB. However, there was no significant difference of GSRS total score between group HM and group FM. The effect of HM was significantly greater than that of orally taking PB in ameliorating the symptoms of rugitus (0.38 versus 0.59,P<0.05), abdominal pain (0.28 versus 0.57,P<0.01), abdominal distension (0.4 versus 0.7,P<0.01), and increased passage of stools (0.06 versus 0.25,P<0.01) at the end of treatment period. In the follow-up period, patients’ therapeutic effect in group HM remained greater than that in group FM (in abdominal pain, abdominal distension, and increased passage of stools) and that in group PB (in loose stools).Conclusions. HM appears to be a promising, efficacious, and well-tolerated treatment for patients with IBS-D.

scholarly journals Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Misako Funaba ◽  
Hitomi Kawanishi ◽  
Yasushi Fujii ◽  
Koyo Higami ◽  
Yoshitoshi Tomita ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Adverse Events ◽  
Cognitive Behavioral Therapy ◽  
Behavioral Therapy ◽  
Dropout Rate ◽  
Interoceptive Exposure ◽  
Face To Face ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, which severely impairs the quality of life of patients. Treatment of refractory IBS patients is needed, but it is not yet widely available. Therefore, we previously developed a Japanese version of cognitive behavioral therapy with interoceptive exposure (CBT-IE) involving 10 face-to-face sessions to treat refractory IBS patients. To disseminate this treatment of IBS in places where therapists are limited, we further developed a hybrid CBT-IE program with complementary video materials that include psychoeducation and homework instructions so that patients can prepare for face-to-face sessions in advance at home and the session time can be shortened, thereby reducing the burden on both patient and therapist. In this study, we conducted a trial to evaluate the feasibility, efficacy, and safety of the hybrid CBT-IE program for Japanese IBS patients. The study was a single-arm, open-label pilot clinical trial. A total of 16 IBS patients were included in the study and 14 patients completed the intervention, which consisted of 10 weekly individual hybrid CBT-IE sessions. We performed an intention to treat analysis. The primary outcome measure for the efficacy of the intervention was a decrease in the severity of IBS symptoms. The feasibility and safety of the intervention were examined by the dropout rate and recording of adverse events, respectively. The dropout rate of the hybrid CBT-IE was comparable to that of our previous CBT-IE with only face-to-face sessions and no adverse events were recorded. The severity of IBS symptoms within-group was significantly decreased from the baseline to mid-treatment [Hedges' g = −0.98 (−1.54, −0.41)], post-treatment [Hedges' g = −1.48 (−2.09, −0.88)], 3-month follow-up [Hedges' g = −1.78 (−2.41, −1.14)], and 6-month follow-up [Hedges' g = −1.76 (−2.39, −1.13)]. Our results suggest that the hybrid CBT-IE is effective and could be conducted safely. To confirm the effectiveness of the hybrid CBT-IE, it is necessary to conduct a multicenter, parallel-design randomized control trial.Clinical Trial Registration: [https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000041376], identifier [UMIN000036327].

scholarly journals Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 928 ◽  
Author(s):  
Antonietta Gerarda Gravina ◽  
Marcello Dallio ◽  
Mario Romeo ◽  
Antonietta Di Somma ◽  
Gaetano Cotticelli ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Symptom Control ◽  
Bowel Dysfunction ◽  
Positive Effects ◽  
Diet Regimen ◽  
Irritable Bowel ◽  
Fodmap Diet ◽  
The Impact

Introduction: Irritable bowel syndrome represents one of the most difficult gastroenterological diseases to treat, that usually induces the patients to follow different drug therapies, often not useful in symptom control. In this scenario low FODMAP diet could have positive effects in patients with irritable bowel syndrome, even because this type of diet regimen is characterized by a low gluten amount due to the exclusion of cereals. Methods: We enrolled 120 patients with irritable bowel syndrome, according to the Rome IV criteria, who were referred to Hepatogastroenterology Division of the University of Campania L. Vanvitelli from June to December 2018. They underwent a low FODMAP diet for six weeks, followed by a gradual weekly reintroduction of every category of food for three months. The patients had a follow-up evaluation for six months after the end of food reintroduction period. We measured abdominal pain with subjective numerical scale from 0 to 10. We evaluated other gastrointestinal symptoms with a questionnaire about symptoms of lower digestive tract, evaluating their frequency and intensity. We also evaluated the impact of irritable bowel syndrome on daily life with neurological bowel dysfunction score. Results: We obtained a good patient-adherence to diet and a statistically significant decrease of abdominal pain, bloating, flatulence, diarrhea, constipation, and neurological bowel dysfunction score (p < 0.001) at the end of the diet. These results remained constant in the follow-up period. Conclusions: We recommend the use of a low FODMAP diet regimen in patients with irritable bowel syndrome in order to control the symptoms and improve the quality of life.

Long-Term Follow-Up of Gut-Directed Hypnotherapy vs. Standard Care in Children With Functional Abdominal Pain or Irritable Bowel Syndrome

2012 ◽  
Vol 107 (4) ◽  
pp. 627-631 ◽  
Author(s):  
Arine M Vlieger ◽  
Juliette M T M Rutten ◽  
Anita M A P Govers ◽  
Carla Frankenhuis ◽  
Marc A Benninga
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Standard Care ◽  
Functional Abdominal Pain ◽  
Long Term Follow Up ◽  
Irritable Bowel

758 Long Term Follow-up of Gut-Directed Hypnotherapy Versus Standard Care in Children With Functional Abdominal Pain or Irritable Bowel Syndrome

2012 ◽  
Vol 142 (5) ◽  
pp. S-134 ◽  
Author(s):  
Arine M. Vlieger ◽  
Juliette M. Rutten ◽  
Anita M. Govers ◽  
Carla Frankenhuis ◽  
Marc A. Benninga
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Standard Care ◽  
Functional Abdominal Pain ◽  
Long Term Follow Up ◽  
Irritable Bowel

scholarly journals A Double Blind Randomized Clinical Trail: Comparing Lactobacillus plantarum 299v with Placebo in treating irritable bowel syndrome patients

2020 ◽  
Author(s):  
Moeen-ul- haq ◽  
Fazl Ullah ◽  
Muhammad Kamran Hassan ◽  
Ahmad Nawaz Babar ◽  
Anwar Ullah
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Lactobacillus Plantarum ◽  
Clinical Symptoms ◽  
Gastrointestinal Disease ◽  
Treated Group ◽  
Significant Difference ◽  
Randomized Control ◽  
Irritable Bowel ◽  
Rectal Emptying

Abstract Irritable bowel syndrome (IBS) is a gastrointestinal disease of intestinal mobility. IBS present with variable clinical symptoms making the treatment difficult. IBS is quiet prevalent around the globe with different frequency. Differences in frequency and gender is due to diet habit. It is less frequent where diary product and vegetable are frequently consumed as compared to those who consumed meat. Lactobacillus plantarum 299v (L. plantarum 299v) is the most widely studied strain in the IBS patients. It is resistant to the actions of intestinal acids and bile, colonizes the human colonic mucosa and is non-pathogenic in nature. The efficacy of Lactobacillus plantarum 299v L is different in different study. The present study was designed to find the efficacy of Lactobacillus plantarum 299v in comparison to placebo in randomized control trial. MethodOne hundred and ninety patients were assessed for eligibility 46 among them were excluded from the study and twenty four declined to participate in the study. One hundred and twenty patient of IBS was grouped in two different groups. The one was treated with Lactobacillus plantarum 299v and the other was treated with placebo. Symptoms of IBS, like abdominal pain, bloating and complete rectal emptying was noted and interpreted among the groups. Results There was no statistically significant difference in relieving abdominal pain, bloating, rectal emptying in Lactobacillus plantarum 299v treated group and placebo treated group. Conclusion This randomized control trail of Lactobacillus plantarum 299v fail to show signicant efficacy in IBS treatment as compared to placebo.

scholarly journals Acupuncture For The Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (ATIBS-D): A Pilot Randomized Controlled Trial

2021 ◽  
Author(s):  
Ling-Yu Qi ◽  
Jing-Wen Yang ◽  
Shi-Yan Yan ◽  
Jian-Feng Tu ◽  
Yan-Fen She ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Adverse Events ◽  
Controlled Trial ◽  
Common Disease ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial ◽  
Irritable Bowel ◽  
Composite Response

Abstract Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common disease without an established optimal treatment. Acupuncture has promising effects on IBS-D, but high-quality evidence is scarce.Methods: In this parallel, multicenter, randomized controlled trial, participants with IBS-D were assigned to three groups: specific acupoints (SA), non-specific acupoints (NSA) and non-acupoints (NA). Participants received 12 sessions (3 sessions per week) treatment over 4 weeks. The primary endpoint was a composite response rate at week 4 of treatment. An eligible composite responder was responded in both abdominal pain intensity and stool consistency, defined as at least 30% decrease in the weekly average of worst abdominal pain score and 50% or greater reduction in the number of Type 6 or 7 stool days weekly compared with baseline.Results: Of 201 screened patients with IBS-D, 90 (44.8%) patients were enrolled, and 88.9% patients completed this study (26 in NSA; 27 in SA and NA). The composite response rates at week 4 were 46.7%, 46.7% and 26.7% (P＞0.05) of the participants who received SA, NSA and NA acupuncture, respectively. Adverse events were reported in 2 (6.7%) patients in SA, 3 (10%) patients in NSA and NA. There were no serious adverse events.Conclusions: The present study suggests that acupuncture treatment is feasible and safe for IBS-D patients. The further adequately powered trials can be achieved by recruiting more patients, increasing treatment dose, prolonging follow-up, choosing specific acupoints, setting up sham-acupuncture control, or a combination thereof.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000030670. Registered on 9 March 2020. https://www.chictr.org.cn/edit.aspx?pid=50167&htm=4

scholarly journals Phenotypic features of patients with post-infectious irritable bowel syndrome

2019 ◽  
Author(s):  
Flaviu Viorel Rusu ◽  
Lorena Mocanu ◽  
Dan Lucian Dumitraşcu
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Demographic Data ◽  
Female Gender ◽  
Sudden Onset ◽  
Published Data ◽  
Tertiary Center ◽  
Significant Difference ◽  
Irritable Bowel ◽  
Post Infectious

Background. Although there are many published data in the literature about irritable bowel syndrome, there are only few data on the long term evolution of patients with post infectious irritable bowel syndrome (PI-IBS) and associated conditions. Aims. The purpose of our research was to study the evolution of PI-IBS patients in a single tertiary center over a period of four years. Study Design. Our research was a longitudinal retrospective study. Methods. We carried out this study based on the survey of the patients records. We recruited two groups of patients: patients with classical IBS and patients with PI-IBS. The IBS diagnosis was established using ROME III criteria, which were used at that time. We compared the two groups of patients by analyzing the demographic data, comorbidities, treatment that was prescribed, and evolution after treatment for a period of 48 month on average. Results. From a total of 592 patients that were diagnosed with IBS between 2013-2016, we identified a subgroup of 64 patients with PI-IBS. These patients were also divided into two subgroups, depending on the main symptoms, 51 with PI-IBS – diarrhea and 13 of them with PI-IBS-constipation. IBS is the most commonly diagnosed among women, 45 patients were women and 15 were men. Regarding the frequency of occurrence of a certain subtype by gender, no significant differences were observed in both IBS and PI-IBS. We noticed a higher incidence of patients residents of an urban community in both groups. The main symptoms were: abdominal pain and bowel disorders (constipation, diarrhea). There was a significant difference between the two groups regarding the onset of the symptoms. From the total of 64 patients with PI-IBS, 88.3% presented a sudden onset of symptoms (mainly abdominal pain) unlike the other group where 81% of them presented a progressive onset, with an insidious progress and sporadic exacerbation. Most patients (65.63%) presented an improvement after the treatment, 25.56% oscillating periods but with a significant decrease of intensity of symptoms, and 7.8% did not show improvement after treatment. The most common associated diseases were depression and anxiety (34.37%). Conclusion IBS is generally present in approximately 11% of the population, with PI-IBS patients accounting for approximately 10% of them. Female gender is more common in both IBS and PI-IBS. Patients with PI-IBS are a burden in the health system in terms of the important economic resources used for diagnosis and treatment.

Efficacy and safety of Trang Phuc Linh Plus tablets in patients with irritable bowel syndrome-diarrhea

2021 ◽  
Vol 148 (12) ◽  
pp. 68-77
Author(s):  
Pham Thi Van Anh ◽  
Nguyen Phuong Thanh ◽  
Dau Thuy Duong ◽  
Nguyen Thi Thuy ◽  
Dang Thi Ngoc Mai ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Group I ◽  
Randomized Phase Ii ◽  
Irritable Bowel ◽  
Diarrhea Syndrome ◽  
Symptom Recurrence

A double-blind, randomized, phase II clinical trial was conducted within a 14-week follow-up including 2 weeks of the non-drug run-in period, 8 weeks of medication, and 4 weeks of follow-up after discontinuation. The objective of the study was to evaluate the efficacy and safety of Trang Phuc Linh Plus in irritable diarrhea syndrome patients. Group I took Trang Phuc Linh Plus 3 tablets/time x 2 times/day for 8 weeks; Group II took placebo 3 tablets/time x 2 times/day for 8 weeks. Patients will be re-examined, tested, and evaluated over the phone for symptom recurrence and adverse events (AEs). This study showed that the Trang Phuc Linh Plus tablets tended to improve symptoms in patients suffering from irritable bowel syndrome with diarrhea, suggesting its safety and tolerability.

scholarly journals Four years Follow-up of Patients with Irritable Bowel Syndrome

2015 ◽  
Vol 53 (1) ◽  
pp. 65-74
Author(s):  
F. Rusu ◽  
Dan L. Dumitraşcu
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Combined Therapy ◽  
Hemorrhoidal Disease ◽  
Associated Diseases ◽  
Tertiary Center ◽  
Rome Iii ◽  
Bowel Disorders ◽  
Irritable Bowel

Abstract There is little data on the long term evolution of patients with irritable bowel syndrome (IBS) and of associated conditions. We therefore studied the evolution of IBS patients in a single tertiary center during a long interval of time. Methods. We carried out a retrospective study based on the survey of patients records. We analyzed the records of symptoms, therapy, associated diseases, as consigned at follow-up visits for an interval of 4 years in average (2008-2011). Results. A cohort of 114 patients with IBS diagnosed based on Rome III criteria were included (29 men and 85 women), age 19-85 years (mean age: 43.45 years). Urban patients were predominant. The main three symptoms were: abdominal pain, bowel disorders (constipation, diarrhea) and bloating. IBS - constipation (IBS - C) is associated with a favorable course of symptoms (increasing the number of stools, decrease intensity of abdominal pain and bloating) after treatment and IBS - diarrhea (IBS - D) is associated with variable symptoms after treatment (p = 0.031). Using trimebutin or mebeverin in association with other drugs for one month correlates with a favorable evolution of symptoms after treatment and monotherapy is associated with fluctuating symptoms ( p< 0.001). Favorable symptoms are associated with the use of probiotics in combination, but not in monotherapy (p< 0.001). Favorable evolution of symptoms is also associated with the use of anxiolytics in combination. Persistence of symptoms after treatment was correlated with the presence or absence of depression. The absence of depression was correlated with a favorable evolution of symptoms (p = 0.005). IBS-C is associated at limit (marginal significance) with hemorrhoidal disease (p = 0.56). 33 patients (29%) - received monotherapy (trimebutin or mebeverin or probiotics); 81 patients (71%) - received combined therapy: (trimebutin or mebeverin or probiotics) + anxiolytics or proton pump inhibitors (PPI) or nonsteroidal anti-inflammatory (NSAI) or spasmolitics. The most common associated diseases observed in patients with IBS were: depression (27.19%), dyslipidemia (25.43%), hemorrhoidal disease (22.80%) and fibromyalgia (21%). Conclusions. The highest response rate was obtained with trimebutin or mebeverin + anxiolitics + probiotics. The most frequent disease associated with IBS was depression. Other diseases with a high incidence: dyslipidemia, hemorrhoidal disease and fibromyalgia. Further studies are needed to analyze the link between IBS and some associated diseases.

Sign in / Sign up

Export Citation Format

Share Document